Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028132 · ClinicalTrials.gov registry record · Phase 1
Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 5
- Study locations
NCT00028132 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 120 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00028132, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the PMPA gel, which kills microbes, in HIV-infected and HIV-uninfected women. The majority of new HIV infections occur through heterosexual contact. A product that stops or slows the replication of HIV during sexual contact is needed. At present, there are no products that are completely effective. PMPA gel, also known as tenofovir, is an anti-microbe agent that may fight against sexual transmission of HIV and other sexually transmitted diseases (STDs). It is applied to the vagina and gives women the ability to control their disease-prevention activity.
Conditions Studied
Interventions
- DRUG Tenofovir
Study Locations (5)
New York
- Harlem Prevention Ctr. CRS (El-Sadr CTU) - New York
- Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS) - The Bronx
Rhode Island
- The Miriam Hosp., Div. of Infectious Disease - Providence
- Women & Infants' Hosp. - Providence
Pennsylvania
- 3535 Market Street CRS - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028132
The ClinicalTrials.gov registry entry for NCT00028132 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir is the first listed.
NCT00028132 reports 5 study locations spanning 3 distinct geographic areas - top geographies include New York, Rhode Island, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00028132 about?
NCT00028132 is a clinical study titled "Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel". The purpose of this study is to evaluate the PMPA gel, which kills microbes, in HIV-infected and HIV-uninfected women. The majority of new HIV infections occur through heterosexual contact. A product that stops or slows the replication of HIV during sexual contact is needed. At present, there are n...
What is the current status of trial NCT00028132?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. Estimated completion is 2005-12.
What conditions does trial NCT00028132 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00028132?
The interventions under investigation include: Tenofovir (DRUG).
Who is sponsoring clinical trial NCT00028132?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00028132 being conducted?
This trial has 5 study locations across New York, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.